Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?
The company may be on track to its next product.
Overview
Moderna (NASDAQ:MRNA) shareholders have seen this before: The biotech makes a game-changing advancement, and the stock takes off. The first notable occurrence was during early pandemic days, when the company brought its coronavirus vaccine from the drawing board to commercialization in less than a year. Investors rushed to get in on this innovative company, driving the stock to a 2,000% gain from 2020 through early August of 2021.
And just recently, investors made a similar move. Moderna announced the positive performance of its personalized mRNA cancer vaccine along with Merck's Keytruda in the combo's first late-stage trial. The stock soared 177% in one trading session and ended the month of August with an increase of about 150%.
Details
Investors have now twice recognized the strength of Moderna's mRNA platform in a big way. Still, Moderna stock in the past hasn't kept its gains -- and after the recent surge, some of the good news may be priced in. Considering the full picture, is the stock a buy, a hold, or a sell? Let's find out.
Source
Originally published at www.fool.com.